Skip to main content
. 2020 Jan 6;69(3):399–405. doi: 10.1007/s00262-019-02462-1

Table 3.

Intracranial efficacy and failed sites of progression of patients with BMS who were previously treated with or without brain RT

With prior RT Without prior RT p value
IORR, % 25 31.3 0.999
IDCR, % 50 43.8 0.723
iPFS, month 2.2 2.2 0.949
OS, month 14.8 NR 0.856
Failed sites of progression, n 0.034
 Intracranial 4 2
 Extracranial 5 2
 Both 5 8

NR not reached